Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas.

Aggressive growth Cavernous sinus Interdisciplinary management Invasive adenoma Pituitary carcinomas Transcranial surgery Transsphenoidal surgery

Journal

Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 6 6 2020
medline: 28 9 2021
entrez: 6 6 2020
Statut: ppublish

Résumé

Surgery of aggressive pituitary adenomas and pituitary carcinomas is part of the interdisciplinary management of these difficult to treat tumors. Invasion, giant size and unusual, asymmetric extent of these tumors frequently require modifications or extensions of the standard approaches for transsphenoidal and transcranial surgery. Frequently, only debulking procedures can be performed. In aggressive and hormone secreting adenomas, the remission rates achieved by surgery alone are relatively poor and adjuvant medical treatments or irradiation are needed. Safe resection of as much tumor as possible and symptomatic control is aimed at, rather than remission. Many procedures are required for rapid progression of lesions or recurrences, in order to extend the survival of the patients. Metastases of pituitary carcinomas within the cranial cavity or spine can be attacked. Since they can occur anywhere in the brain or spinal canal they require the entire battery of neurosurgical approaches. Unfortunately, in this group of pituitary tumors, the complication rates are higher than in primary operations of enclosed adenomas. The respective techniques with their facilities and limitations are reviewed in this article.

Identifiants

pubmed: 32500483
doi: 10.1007/s11154-020-09563-8
pii: 10.1007/s11154-020-09563-8
pmc: PMC7303081
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-261

Références

J Spinal Cord Med. 2012 Mar;35(2):118-21
pubmed: 22333938
Acta Neurochir (Wien). 1988;92(1-4):93-9
pubmed: 3407479
J Neurosurg. 2018 Sep 7;131(1):131-140
pubmed: 30192191
Neurosurgery. 2004 Sep;55(3):539-47; discussion 547-50
pubmed: 15335421
J Neurol Surg B Skull Base. 2018 Oct;79(Suppl 4):S311-S315
pubmed: 30210983
Neurosurgery. 1984 Apr;14(4):485-8
pubmed: 6728153
Neurosurgery. 2005 Jun;56(6):1222-33; discussion 1233
pubmed: 15918938
Neuroendocrinology. 2016;103(1):32-41
pubmed: 26536097
J Neurosurg. 2019 May 31;132(6):1739-1746
pubmed: 31151112
Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101299
pubmed: 31431397
J Neurosurg. 2015 Apr;122(4):803-11
pubmed: 25658782
J Clin Endocrinol Metab. 2011 Sep;96(9):2732-40
pubmed: 21715544
J Clin Endocrinol Metab. 2005 May;90(5):3089-99
pubmed: 15741248
J Neurooncol. 2017 Apr;132(2):313-321
pubmed: 28074324
J Neurosurg. 2013 Mar;118(3):613-20
pubmed: 23240699
Arch Otolaryngol Head Neck Surg. 2009 Dec;135(12):1219-24
pubmed: 20026819
Eur J Endocrinol. 2015 Jun;172(6):707-13
pubmed: 25792375
World Neurosurg. 2010 Jul;74(1):161-4
pubmed: 21300008
J Neurooncol. 2004 Aug-Sep;69(1-3):237-56
pubmed: 15527094
Zh Vopr Neirokhir Im N N Burdenko. 2013;77(6):28-37; discussion 38
pubmed: 24558752
Clin Neurosurg. 1969;16:185-217
pubmed: 5811707
Endocr Relat Cancer. 2018 Nov 01;25(11):R559–R575
pubmed: 30306782
World Neurosurg. 2018 Sep;117:e280-e289
pubmed: 29906579
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
Int J Oral Maxillofac Surg. 2000 Apr;29(2):128-30
pubmed: 10833150
Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5
pubmed: 18031313
Neurosurgery. 1997 Sep;41(3):542-50; discussion 551-2
pubmed: 9310970
Front Horm Res. 2006;34:1-28
pubmed: 16474213
Eur J Endocrinol. 2018 Jan;178(1):G1-G24
pubmed: 29046323
Eur J Endocrinol. 2018 Mar;178(3):265-276
pubmed: 29330228
Surg Neurol. 2002 Jun;57(6):380-90; discussion 390
pubmed: 12176196
Pituitary. 2008;11(4):375-84
pubmed: 18421581
Neurosurgery. 1997 Feb;40(2):225-36; discussion 236-7
pubmed: 9007854
J Neurosurg. 2018 Jun 1;:1-8
pubmed: 29999459
Neurosurg Clin N Am. 2019 Oct;30(4):445-455
pubmed: 31471051

Auteurs

Michael Buchfelder (M)

Department of Neurosurgery, University Hospital Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany. Michael.Buchfelder@uk-erlangen.de.

Sven-Martin Schlaffer (SM)

Department of Neurosurgery, University Hospital Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH